A tumor-targeted trimeric 4-1BB-agonistic antibody induces potent anti-tumor immunity without systemic toxicity

The costimulation of immune cells using first-generation anti-4-1BB monoclonal antibodies (mAbs) has demonstrated anti-tumor activity in human trials. Further clinical development, however, is restricted by significant off-tumor toxicities associated with FcγR interactions. Here, we have designed an...

Descripción completa

Detalles Bibliográficos
Autores principales: Compte, Marta, Harwood, Seandean Lykke, Muñoz, Ines G., Navarro, Rocio, Zonca, Manuela, Perez-Chacon, Gema, Erce-Llamazares, Ainhoa, Merino, Nekane, Tapia-Galisteo, Antonio, Cuesta, Angel M., Mikkelsen, Kasper, Caleiras, Eduardo, Nuñez-Prado, Natalia, Aznar, M. Angela, Lykkemark, Simon, Martínez-Torrecuadrada, Jorge, Melero, Ignacio, Blanco, Francisco J., Bernardino de la Serna, Jorge, Zapata, Juan M., Sanz, Laura, Alvarez-Vallina, Luis
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2018
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6237851/
https://www.ncbi.nlm.nih.gov/pubmed/30442944
http://dx.doi.org/10.1038/s41467-018-07195-w

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6237851/
https://www.ncbi.nlm.nih.gov/pubmed/30442944
http://dx.doi.org/10.1038/s41467-018-07195-w

Ejemplares similares